- Home
- TLSI vs EHI Comparison
TLSI vs EHI Comparison
Compare TLSI & EHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- EHI
- Stock Information
- Founded
- TLSI 2010
- EHI 2003
- Country
- TLSI United States
- EHI United States
- Employees
- TLSI N/A
- EHI N/A
- Industry
- TLSI Medical Specialities
- EHI Investment Managers
- Sector
- TLSI Health Care
- EHI Finance
- Exchange
- TLSI Nasdaq
- EHI Nasdaq
- Market Cap
- TLSI 124.9M
- EHI N/A
- IPO Year
- TLSI N/A
- EHI N/A
- Fundamental
- Price
- TLSI $4.69
- EHI $6.61
- Analyst Decision
- TLSI Strong Buy
- EHI
- Analyst Count
- TLSI 6
- EHI 0
- Target Price
- TLSI $11.75
- EHI N/A
- AVG Volume (30 Days)
- TLSI 36.4K
- EHI 44.5K
- Earning Date
- TLSI 11-14-2024
- EHI 01-01-0001
- Dividend Yield
- TLSI N/A
- EHI 11.54%
- EPS Growth
- TLSI N/A
- EHI N/A
- EPS
- TLSI N/A
- EHI N/A
- Revenue
- TLSI $26,891,000.00
- EHI N/A
- Revenue This Year
- TLSI $60.96
- EHI N/A
- Revenue Next Year
- TLSI $53.65
- EHI N/A
- P/E Ratio
- TLSI N/A
- EHI N/A
- Revenue Growth
- TLSI 67.90
- EHI N/A
- 52 Week Low
- TLSI $3.50
- EHI $6.00
- 52 Week High
- TLSI $10.42
- EHI $7.75
- Technical
- Relative Strength Index (RSI)
- TLSI 51.68
- EHI 45.46
- Support Level
- TLSI $4.72
- EHI $6.52
- Resistance Level
- TLSI $5.32
- EHI $6.65
- Average True Range (ATR)
- TLSI 0.31
- EHI 0.07
- MACD
- TLSI 0.01
- EHI -0.00
- Stochastic Oscillator
- TLSI 47.52
- EHI 50.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.